On January 20, 2021 EDAP TMS SA (Nasdaq: EDAP) ("the Company"), the global leader in robotic energy-based therapies, reported that preliminary unaudited fourth quarter and full-year revenue for the three and twelve months ended December 31, 2020 (Press release, EDAP TMS, JAN 20, 2021, View Source [SID1234574143]). For the fourth quarter 2020, the Company anticipates record revenue of EUR 15.3 million [$18.3 million], as compared to EUR 12.0 million [$13.3 million] for the fourth quarter of 2019, an increase of 28%. For the full-year 2020, unaudited revenue is anticipated to be EUR 41.6 million [$47.8 million], as compared to EUR 44.9 million [$50.2 million] for the full-year 2019, a decrease of 7%, driven entirely by COVID-19-related restrictions.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Marc Oczachowski, EDAP’s Chairman and Chief Executive Officer, said: "We are very pleased with this very strong and successful fourth quarter during which we generated record revenue that increased 28% over the prior year period. Of note, HIFU revenue increased 50% over the fourth quarter of 2019, which is all the more impressive in light of the impact the pandemic continues to have on healthcare systems around the world. This reflects the continued interest in HIFU technology and confirms that we have successfully adjusted to this new reality by continuing to grow our sales pipeline. We entered 2021 with renewed momentum, and I look forward to an exciting year."

Note: exchange rates used in the conversion of EUR to USD are: Q4 2020=1.194 and full year 2020=1.147.